AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38051008 — intervention group
Group type: EXPERIMENTAL
Intervention: EnhanceFitness (EF) physical activity intervention, 12-week duration, thrice weekly classes
Number of subjects: 323
Study 38051008 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (wait-list control)
Number of subjects: 323
Study 38051029 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MRI with T2 and diffusion-weighted imaging (DWI)
Number of subjects: 50
Study 38051146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 0
Study 38051184 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT plus SM
Number of subjects: 49462
Study 38051184 — intervention group
Group type: COMPARATOR
Intervention: DM
Number of subjects: 49462
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilocular cysts
Number of subjects: 2638
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Septated cysts
Number of subjects: 2638
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysts smaller than 3 cm
Number of subjects: 2638
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysts larger than 6 cm
Number of subjects: 2638
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2638
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal status
Number of subjects: 2638
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Older than age 70 years
Number of subjects: 2638
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using hormone therapy
Number of subjects: 2638
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 2638
Study 38051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of ovarian cancer
Number of subjects: 2638
Study 38051303 — intervention group
Group type: EXPERIMENTAL
Intervention: AK8 gene association with neurocognitive function changes
Number of subjects: 229
Study 38051303 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPRZ1, MUC16, TNRC6C-AS1 gene associations with anxiety
Number of subjects: 229
Study 38051303 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNF382 gene association with neurocognitive deficits in males
Number of subjects: 229
Study 38051303 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL2 and C6orf165 gene associations with anxiety
Number of subjects: 229
Study 38051303 — intervention group
Group type: EXPERIMENTAL
Intervention: EXO5 gene association with depression
Number of subjects: 229
Study 38051303 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2W1 and PCMTD1 gene associations with depression (modulatory effect of rare variants)
Number of subjects: 229
Study 38051303 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNF382 gene association in combined cohorts (males)
Number of subjects: 229
Study 38051303 — intervention group
Group type: EXPERIMENTAL
Intervention: EXO5 gene association with depression in combined cohorts
Number of subjects: 229
Study 38051326 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 459
Study 38051326 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 459
Study 38051327 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial amnioinfusions of isotonic fluid before 26 weeks' gestation
Number of subjects: 21
Study 38051327 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of amnioinfusions
Number of subjects: 21
Study 38051327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age greater than 32 weeks
Number of subjects: 21
Study 38051327 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher birth weight
Number of subjects: 21
Study 38051327 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival to hospital discharge while receiving peritoneal dialysis
Number of subjects: 21
Study 38051328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy (capecitabine and oxaliplatin, XELOX regimen)
Number of subjects: 650
Study 38051328 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (capecitabine and oxaliplatin, XELOX regimen)
Number of subjects: 650
Study 38051328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 650
Study 38051328 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 650
Study 38051631 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 16
Study 38051631 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 16
Study 38051647 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS and tissue factor induced thrombin generation
Number of subjects: 117
Study 38051647 — intervention group
Group type: EXPERIMENTAL
Intervention: HRG levels
Number of subjects: 117
Study 38051647 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C concentration
Number of subjects: 117
Study 38051647 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin concentration
Number of subjects: 117
Study 38051647 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein S concentration
Number of subjects: 117
Study 38051678 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted lenticule extraction (LALEX)
Number of subjects: 108
Study 38051678 — intervention group
Group type: COMPARATOR
Intervention: Femtosecond laser in situ keratomileusis (FS-LASIK)
Number of subjects: 108
Study 38051699 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS reminders for TB patients and notifications to social supporters for 3 months, then triggered by late or missed dosing for 3 months.
Number of subjects: 63
Study 38051699 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly SMS reminders for TB patients and notifications to social supporters for 3 months, then triggered by late or missed dosing for 3 months.
Number of subjects: 63
Study 38051699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS).
Number of subjects: 63
Study 38051700 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced vitamin supplement
Number of subjects: 1729
Study 38051700 — intervention group
Group type: COMPARATOR
Intervention: Standard vitamin supplement (control)
Number of subjects: 1729
Study 38051723 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT) combined with exercise (balance, strengthening, and mobility exercises guided by 15-minute action observation videos before a 45-minute exercise session)
Number of subjects: 100
Study 38051723 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (same exercises without action observation)
Number of subjects: 100
Study 38051740 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus spp.)
Number of subjects: 120
Study 38051740 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 120
Study 38051740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 38051750 — intervention group
Group type: EXPERIMENTAL
Intervention: Peposertib 50-250 mg once daily plus capecitabine 825 mg/m2 twice daily and radiotherapy 5 days per week
Number of subjects: 19
Study 38051750 — intervention group
Group type: EXPERIMENTAL
Intervention: Peposertib 100 mg cohort
Number of subjects: 19
Study 38051750 — intervention group
Group type: EXPERIMENTAL
Intervention: Peposertib ≤150 mg once daily
Number of subjects: 19
Study 38051750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicities
Number of subjects: 19
Study 38051993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir
Number of subjects: 0
Study 38051993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38052037 — intervention group
Group type: EXPERIMENTAL
Intervention: VRD maintenance (bortezomib, lenalidomide, dexamethasone) for 3 years
Number of subjects: 177
Study 38052038 — intervention group
Group type: EXPERIMENTAL
Intervention: TAG-AZA-VEN
Number of subjects: 56
Study 38052042 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg subcutaneously once weekly
Number of subjects: 0
Study 38052042 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 0
Study 38052042 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study 38052059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Number of subjects: 0
Study 38052073 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Health Center Staff in Culturally Responsive Care
Number of subjects: 0
Study 38052073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 38052215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 360
Study 38052215 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 360
Study 38052273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradycardia (BRADY)
Number of subjects: 0
Study 38052273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-CPR pulse pressure >20 mmHg
Number of subjects: 0
Study 38052273 — intervention group
Group type: COMPARATOR
Intervention: Pulseless electrical activity (PEA)
Number of subjects: 0
Study 38052302 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich oral nutritional supplement for 4 weeks before TAVR with home-based supervised exercise sessions for 12 weeks after TAVR
Number of subjects: 200
Study 38052302 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care lifestyle education
Number of subjects: 200
Study 38052376 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitation-IVM (CAPA-IVM)
Number of subjects: 46
Study 38052376 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 46
Study 38052709 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 0
Study 38052851 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDF treatment of human skin fibroblast (HSF) cell lines with different concentrations and durations.
Number of subjects: 74
Study 38052851 — intervention group
Group type: COMPARATOR
Intervention: Psoriatic patients (no specific intervention mentioned, observational).
Number of subjects: 74
Study 38052910 — intervention group
Group type: EXPERIMENTAL
Intervention: Divarasib plus cetuximab
Number of subjects: 29
Study 38053101 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes toward drugs measured by the Drug Attitude Inventory (DAI-10) at baseline
Number of subjects: 0
Study 38053101 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DAI-10 total score greater than -1
Number of subjects: 0
Study 38053101 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of the disease (CGI-s) and insight regarding the disease
Number of subjects: 0
Study 38053114 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity coaching
Number of subjects: 30
Study 38053114 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity coaching
Number of subjects: 30
Study 38053114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention alarm use
Number of subjects: 30
Study 38053114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall rates
Number of subjects: 30
Study 38053114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall-related injuries
Number of subjects: 30
Study 38053114 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation outcomes
Number of subjects: 30
Study 38053122 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Brief Cognitive Behavioral Therapy (G-BCBT)
Number of subjects: 136
Study 38053122 — intervention group
Group type: COMPARATOR
Intervention: Dialectical Behavior Therapy (DBT) Skills Group
Number of subjects: 136
Study 38053197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level light therapy
Number of subjects: 106
Study 38053197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 106
Study 38053196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (TUDCA) as add-on therapy to riluzole
Number of subjects: 0
Study 38053196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 38053456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricaemia
Number of subjects: 3628
Study 38053515 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly somatrogon
Number of subjects: 0
Study 38053515 — intervention group
Group type: COMPARATOR
Intervention: Once-daily somatropin
Number of subjects: 0
Study 38053534 — intervention group
Group type: EXPERIMENTAL
Intervention: KmAsthma self-management app
Number of subjects: 120
Study 38053657 — intervention group
Group type: EXPERIMENTAL
Intervention: H-IGRT (hypofractionated 15 fractions/3 weeks image-guided radiation therapy)
Number of subjects: 123
Study 38053657 — intervention group
Group type: COMPARATOR
Intervention: CRT (normofractionated 25-33 fractions/5-7 weeks conventional radiation therapy)
Number of subjects: 123
Study 38053659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (25-40 Gy/5 Fx for cohort A; 15-30 Gy/5 Fx for cohort B), chemotherapy, toripalimab, and stereotactic ablative radiotherapy (SABR) for all metastatic lesions.
Number of subjects: 0
Study 38053744 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive remediation (MCR) for 6 months
Number of subjects: 22
Study 38053744 — intervention group
Group type: COMPARATOR
Intervention: Computerized cognitive remediation (CCR) for 6 months
Number of subjects: 22
Study 38053913 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM)
Number of subjects: 114
Study 38053913 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarker panels
Number of subjects: 114
Study 38053913 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed new diagnostic criterion
Number of subjects: 114
Study 38054019 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM)
Number of subjects: 0
Study 38054019 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive neuromuscular stretching (PNF)
Number of subjects: 0
Study 38054386 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 0
Study 38054504 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic-phase ICH patients
Number of subjects: 22
Study 38054504 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 22
Study 38054535 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred HIV prevention model delivered by community health workers (CHWs) with clinician support; included structured client choice of product (PrEP or PEP), service location, and HIV testing modality, personalized support plan, and 24/7 clinician access.
Number of subjects: 429
Study 38054535 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred HIV prevention model delivered by community health workers (CHWs) with clinician support.
Number of subjects: 429
Study 38054535 — intervention group
Group type: COMPARATOR
Intervention: Control group referred to local health facilities for HIV prevention services delivered by Ministry of Health staff.
Number of subjects: 429
Study 38054555 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper hemi-sternotomy
Number of subjects: 1395
Study 38054564 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, skills-based alcohol intervention with baseline and 3-month in-person counselling sessions and interim booster phone calls every 3 weeks.
Number of subjects: 401
Study 38054564 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, skills-based alcohol intervention.
Number of subjects: 401
Study 38054604 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE's Tipping Point Program
Number of subjects: 0
Study 38054696 — intervention group
Group type: EXPERIMENTAL
Intervention: JX11502MA 0.25 mg
Number of subjects: 0
Study 38054696 — intervention group
Group type: EXPERIMENTAL
Intervention: JX11502MA 0.5 mg
Number of subjects: 0
Study 38054696 — intervention group
Group type: EXPERIMENTAL
Intervention: JX11502MA 1 mg
Number of subjects: 0
Study 38054696 — intervention group
Group type: EXPERIMENTAL
Intervention: JX11502MA 2 mg
Number of subjects: 0
Study 38054696 — intervention group
Group type: EXPERIMENTAL
Intervention: JX11502MA 3 mg
Number of subjects: 0
Study 38054696 — intervention group
Group type: EXPERIMENTAL
Intervention: JX11502MA 6 mg
Number of subjects: 0
Study 38054696 — intervention group
Group type: EXPERIMENTAL
Intervention: JX11502MA 8 mg
Number of subjects: 0
Study 38054696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38054726 — intervention group
Group type: EXPERIMENTAL
Intervention: FL058 alone
Number of subjects: 0
Study 38054726 — intervention group
Group type: EXPERIMENTAL
Intervention: FL058 in combination with meropenem
Number of subjects: 0
Study 38054726 — intervention group
Group type: EXPERIMENTAL
Intervention: FL058/meropenem combination
Number of subjects: 0
Study 38054932 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic choice patient-centered intervention (travel pack, multimonth and offsite refills, facilitated transfer, hotline access)
Number of subjects: 201
Study 38054932 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic choice patient-centered intervention
Number of subjects: 201
Study 38054932 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 38055007 — intervention group
Group type: EXPERIMENTAL
Intervention: PICU admission
Number of subjects: 296
Study 38055007 — intervention group
Group type: COMPARATOR
Intervention: Non-PICU group
Number of subjects: 296
Study 38055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-pathway inhibition (DPI) with rivaroxaban and low-dose aspirin
Number of subjects: 33
Study 38055186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Number of subjects: 690
Study 38055186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil after clinical worsening
Number of subjects: 690
Study 38055186 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by oral treprostinil after clinical worsening
Number of subjects: 690
Study 38055237 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring strategy (4 daily SMS messages)
Number of subjects: 699
Study 38055237 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 699
Study 38055237 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring strategy
Number of subjects: 699
Study 38055237 — intervention group
Group type: COMPARATOR
Intervention: Telemonitoring strategy and Standard care
Number of subjects: 699
Study 38055242 — intervention group
Group type: EXPERIMENTAL
Intervention: RGRN-305, 250-mg tablet, once daily for 16 weeks
Number of subjects: 15
Study 38055242 — intervention group
Group type: COMPARATOR
Intervention: Placebo, matching tablet, once daily for 16 weeks
Number of subjects: 15
Study 38055242 — intervention group
Group type: EXPERIMENTAL
Intervention: RGRN-305
Number of subjects: 15
Study 38055242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 38055242 — intervention group
Group type: COMPARATOR
Intervention: RGRN-305 and Placebo
Number of subjects: 15
Study 38055253 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV) 6 mg/kg every 3 weeks
Number of subjects: 453
Study 38055253 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan)
Number of subjects: 453
Study 38055253 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV)
Number of subjects: 453
Study 38055253 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 453
Study 38055280 — intervention group
Group type: EXPERIMENTAL
Intervention: HCW-collected throat specimens
Number of subjects: 2674
Study 38055280 — intervention group
Group type: EXPERIMENTAL
Intervention: HCW-collected nasal specimens
Number of subjects: 2674
Study 38055280 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected nasal specimens
Number of subjects: 2674
Study 38055280 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected throat specimens
Number of subjects: 2674
Study 38055280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining nasal and throat specimens (HCW-collected)
Number of subjects: 2674
Study 38055280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining nasal and throat specimens (self-collected)
Number of subjects: 2674
Study 38055283 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 73
Study 38055283 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 73
Study 38055283 — intervention group
Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 73
Study 38055283 — intervention group
Group type: COMPARATOR
Intervention: ECT
Number of subjects: 73
Study 38055284 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Number of subjects: 457
Study 38055284 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 457
Study 38055284 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-BARI Score
Number of subjects: 457
Study 38055284 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-BARI Score QOL
Number of subjects: 457
Study 38055309 — intervention group
Group type: EXPERIMENTAL
Intervention: VR multiplayer recreation and socialization using Meta Quest 2 headset, 4 weeks duration, 2×1-hour sessions per week.
Number of subjects: 12
Study 38055353 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided stereotactic body radiation therapy (SBRT) with 40 Gy prescribed to 95% of the PTV in over five fractions
Number of subjects: 69
Study 38055353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid model combining dosimetric features with clinical parameters
Number of subjects: 69
Study 38055353 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive grouped greedy algorithm (IGA) for dosimetric feature selection
Number of subjects: 69
Study 38055353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosimetric features selected by IGA
Number of subjects: 69
Study 38055641 — intervention group
Group type: EXPERIMENTAL
Intervention: High Healthy Eating Index (HEI ≥ 58.89)
Number of subjects: 119